Objective To develop a brain tumor model in mouse where drugs could be convection-enhanced delivered via a mini-osmotic pump directly into a pre-established tumor bed. Methods Supratentorial tumors were established in 14 cases athymic nude mice which xenografts with lucifeased-modified human glioblastoma U87 cells lines and a mini-osmotic pump for convection-ehanced delivery therapeutic drugs were implanted into the body of the mice, the mice were subsequently assigned randomly to control and DTATEGF treatment groups, and the survival time were analyzed using Kaplan-Meier survival curve. Results There were no noticeable side effects of maintaining the device in place for long periods of time. The device never moved or came off the scalp, all nude mice tolerated the device well. No morbidity or mortality was observed, and no infections were seen. Survival analysis revealed that the median survival of mice treated with DTATEGF was significantly extended relative to controls (126 days vs. 68 days, P=0.0002). Histopathologic analysis revealed tumor growth within the cerebral in all mice. Conclusions This model is well suited for pre-clinical testing of the effects of various treatment strategies on established brain tumors in a mouse model which more closely simulates the clinical situation. The Results of these experiments indicate that DTATEGF can be delivered by convent-enhanced delivery (CED) via micr-osmotic pump to intracranial tumor and be successful in providing additional survival benefit.